Who are Brexpiprazole +ADT's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abilify MyCite®, Adjunct brexpiprazole, Aripiprazole (Fixed dose).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/brexpiprazole-adt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Brexpiprazole +ADT — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Brexpiprazole +ADT (Brexpiprazole +ADT) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic (dopamine D2 partial agonist). Area: Psychiatry / Mental Health.

phase 3 Atypical antipsychotic (dopamine D2 partial agonist) Dopamine D2 receptor, Serotonin 5-HT1A receptor Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Brexpiprazole +ADT (Brexpiprazole +ADT) — Otsuka Pharmaceutical Development & Commercialization, Inc.. Brexpiprazole is an atypical antipsychotic that acts as a dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist, combined with adjunctive antidepressant therapy (ADT) to treat major depressive disorder.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Brexpiprazole +ADT TARGET	Brexpiprazole +ADT	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Atypical antipsychotic (dopamine D2 partial agonist)	Dopamine D2 receptor, Serotonin 5-HT1A receptor
Abilify MyCite®	Abilify MyCite®	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic with digital adherence monitoring	Dopamine D2 receptor, serotonin 5-HT1A receptor
Adjunct brexpiprazole	Adjunct brexpiprazole	H. Lundbeck A/S	phase 3	Serotonin-dopamine activity modulator (SDAM)	Dopamine D2 receptor, Serotonin 5-HT1A receptor
Aripiprazole (Fixed dose)	Aripiprazole (Fixed dose)	Otsuka Pharmaceutical Co., Ltd.	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic (dopamine D2 partial agonist) class)

Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brexpiprazole +ADT — Competitive Intelligence Brief. https://druglandscape.com/ci/brexpiprazole-adt. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing